Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimapitide - Auris Medical/Xigen

Drug Profile

Brimapitide - Auris Medical/Xigen

Alternative Names: AM-111; AM111 peptide; D-JNKI-1; Sonsuvi; XG-102; XG102 peptide

Latest Information Update: 22 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xigen
  • Developer Auris Medical; ribOvax Biotechnologies; Xigen
  • Class Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Peptides; Urologics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ocular inflammation; Sensorineural hearing loss
  • Preclinical Alzheimer's disease; Interstitial cystitis; Kidney disorders
  • No development reported Eye disorders; Stroke
  • Discontinued Ear disorders; Myocardial infarction; Parkinson's disease; Transplant rejection

Most Recent Events

  • 15 Nov 2018 Brimapitide is available for licensing as of 15 Nov 2018. www.aurismedical.com
  • 15 Aug 2018 Auris Medical expects the US FDA's feedback regarding the regulatory path for AM 111 during the third quarter of 2018
  • 07 May 2018 Auris Medical intends to request a Type C meeting with US FDA for regulatory discussions related with potential approval in Sensorineural hearing loss
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top